# Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle

> **NCT03267264** · NA · COMPLETED · sponsor: **Becton, Dickinson and Company** · enrollment: 248 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DEVICE:** BD Nano™ vs Nucleus
- **DEVICE:** NovoFine® vs Nucleus
- **DEVICE:** NovoTwist®/NovoFine® Plus vs Nucleus
- **DEVICE:** Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus

## Key facts

- **NCT ID:** NCT03267264
- **Lead sponsor:** Becton, Dickinson and Company
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-01
- **Primary completion:** 2018-04-24
- **Final completion:** 2018-05-24
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2019-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03267264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03267264, "Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03267264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*